← Back to patent-cliff list
CAS 53067-82-6
(8S,9S,10R,11R,13S,14S)-13-ethyl-11-hydroxy-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione
Codes: ETON-001
Application context (from source-drug indications)
ContraceptionEtonogestrelAcquired immunodeficiency syndromeEtonogestrelDysmenorrhoeaEtonogestrel血崩EtonogestrelBenign prostatic hyperplasiaEtonogestrel月经失调Etonogestrel
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Etonogestrel | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(8S,9S,10R,11R,13S,14S)-13-ethyl-11-hydroxy-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→(8'S,9'S,10'R,13'S,14'S)-13'-ethyl-1',2',6',7',8',9',10',12',13',14',15',16'-dodecahydro-11'H-dispiro[[1,3]dioxolane-2,3'-cyclopenta[a]phenanthrene-17',2''-[1,3]dioxolan]-11'-one→methyltriphenylphosphonium bromide→(8'S,9'S,10'R,13'S,14'S)-13'-ethyl-11'-methylene-1',6',7',8',9',10',11',12',13',14',15',16'-dodecahydro-2'H-dispiro[[1,3]dioxolane-2,3'-cyclopenta[a]phenanthrene-17',2''-[1,3]dioxolane]→(8S,9S,10R,13S,14S)-13-ethyl-11-methylene-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→pyrrolidine→(8S,9S,10R,13S,14S)-13-ethyl-11-methylene-3-(pyrrolidin-1-yl)-1,2,7,8,9,10,11,12,13,14,15,16-dodecahydro-17H-cyclopenta[a]phenanthren-17-one→ethyne→(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylene-3-(pyrrolidin-1-yl)-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol
(8S,9S,10R,11R,13S,14S)-13-ethyl-11-hydroxy-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→ethyne→(8S,9S,10R,11R,13S,14S)-13-ethyl-11-hydroxy-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dithiolan]-17(2H)-one→(8'S,9'S,10'R,11'R,13'S,14'S)-13'-ethyl-1',6',7',8',9',10',11',12',13',14',15',16'-dodecahydro-2'H-dispiro[[1,3]dioxolane-2,17'-cyclopenta[a]phenanthrene-3',2''-[1,3]dithiolan]-11'-ol→(8'S,9'S,10'R,13'S,14'S)-13'-ethyl-1',2',6',7',8',9',10',12',13',14',15',16'-dodecahydro-11'H-dispiro[[1,3]dioxolane-2,17'-cyclopenta[a]phenanthrene-3',2''-[1,3]dithiolan]-11'-one→(8S,9S,10R,13S,14S)-13-ethyl-11-methylene-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dithiolan]-17(2H)-one→(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylene-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dithiolan]-17-ol
(8S,9S,10R,11R,13S,14S)-13-ethyl-11-hydroxy-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→(8S,9S,10R,13S,14S)-13-ethyl-11-methylene-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione→(8S,9S,10R,13S,14S)-13-ethyl-6,7,8,9,10,12,13,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,11,17(2H)-trione→(8S,9S,10R,13S,14S)-13-ethyl-1,2,4,7,8,9,10,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolane]-11,17-dione→(8S,9S,10R,13S,14S)-13-ethyl-17-hydroxy-1,4,7,8,9,10,12,13,14,15,16,17-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-11(2H)-one→(8S,9S,10R,13S,14S)-13-ethyl-11-methylene-1,2,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17-ol→(8S,9S,10R,13S,14S)-13-ethyl-11-methylene-1,4,7,8,9,10,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxolan]-17(2H)-one
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.